Cystinuria is defined as an inherited disorder characterized by increased urinary excretion of cystine and the dibasic amino acids arginine, lysine and ornithine. The only clinical manifestation of cystinuria is renal cystine stone formation due to the low solubility of cystine in the urine. Cystinuria can be attributed to mutations in the SLC3A1 and SLC7A9 genes in the majority of all cases and it has been a common expectation that molecular genetic studies of cystinuria would aid in understanding of the varying clinical outcome seen in the disease. Besides human, the disease has been most extensively studied in the domestic dog. The present study was undertaken to investigate the molecular genetic basis of cystinuria in patients from Sweden and to correlate genetic findings with phenotypes produced regarding cystine and dibasic amino acid excretion. Further, attempts were made to elucidate the molecular genetics of cystinuria in the dog. The entire coding sequences of the SLC3A1 and SLC7A9 genes were analysed by means of SSCA and DNA sequencing in 53 cystinuria patients and genetic findings were related to urinary excretion of cystine and dibasic amino acids in a subset of the patient group. We detected a total number of 22 different mutations in the SLC3A1 and SLC7A9 genes, 18 of which were described for the first time. We have found a probable genetic cause of cystinuria in approximately 74 % of our patients and a possible contribution to the disease in another 19 %. Mutations in the SLC3A1 gene is the major cause of cystinuria in our group, with only a minor contribution of SLC7A9 mutations. The group of patients presenting SLC3A1 mutations in a heterozygous state or lacking mutations in both genes had higher values of total urinary cystine and dibasic amino acids compared to patients homozygous for SLC3A1 mutations. The reason for this discrepancy remains unclear, but the possible impact of medical treatment with sulfhydryl compounds on total cystine values was ruled out. Sequencing of the full-length canine SLC7A9 cDNA was accomplished using the RACE technology and results from mutation analyses of SLC7A9 and SLC3A1 in cystinuric dogs showed that only two out of 13 dogs have mutations with possible impact on protein function in these genes. DNA sequencing was used for all exons of both genes in the dog, and in human cystinuria patients, all samples lacking mutations or showing heterozygosity after SSCA screening were sequenced in both genes as well. This implies that all point mutations present have been detected, but the possibility of mutations escaping PCR based methods as well as mutations in regulatory parts of the SLC3A1 and SLC7A9 genes remains in cases lacking a full molecular genetic explanation of the disease. Finally, clinical and genetic data from our study of cystinuria both in man and dog exemplifies that manifestation and clinical severity of cystinuria is not determined by genetic alterations in the SLC3A1 and SLC7A9 alone. Environmental factors, congenital malformations and modulating genetic factors are all possible contributors to the clinical outcome of cystinuria.

Diss. (sammanfattning) Linköping : Linköpings universitet, 2007. / Härtill 4 uppsatser.

Plasma membrane transport proteins play a crucial role in all cells by conferring to the cell surface a selective permeability to a wide range of ions and small molecules. The activity of these transporters is often regulated by controlling their amount at the plasma membrane, via intracellular trafficking. The recent boom in the numbers of crystallized transporters shows that many of them that belong to different functional families with little sequence similarity adopt the same structural fold implying a conserved transport mechanism. These proteins belong to the APC (Amino acid-Polyamine-organoCation) superfamily and their fold is typified by the bacterial leucine transporter LeuT. This LeuT fold is characterized by inverted structural repeats of 5 transmembrane domains that harbor the central substrate-binding site and a pseudo-symmetry axis parallel to the membrane. The yeast Saccharomyces cerevisiae possesses about 16 amino acid permeases (yAAPs) that belong to the APC superfamily and that display various substrate specificity ranges and affinities. Topological, mutational analysis and in silico data indicate that yAAPS adopt the LeuT fold.<p><p>In this work we combined computational modeling and yeast genetics to study substrate binding by yAAPs and the endocytosis of these transporters in response to substrate transport. In the first part of this work, we analyzed the selective recognition of arginine by the yeast specific arginine permease, Can1. We constructed three-dimensional models of Can1 using as a template the recently resolved structure of AdiC, the bacterial arginine:agmatine antiporter, which is also a member of the APC superfamily. By comparison of the binding pockets of Can1 and Lyp1, the yeast specific lysine permease, we identified key residues that are involved in the recognition of the main and side chains of arginine. We first showed that the network of interactions of arginine in Can1 is similar to that of AdiC, and that the selective recognition of arginine is mediated by two residues: Asn 176 and Thr 456. Substituting these residues by their corresponding residues in Lyp1 converted Can1 into a specific lysine permease. In the second part of this work, we studied the regulation of two permeases, Can1 and the yeast general amino acid permease, Gap1. In the presence of their substrates, Gap1 and Can1 undergo ubiquitin-dependent endocytosis and targeting to the vacuolar lumen for degradation. We showed that this downregulation is not due to intracellular accumulation of the transported amino acids but to transport catalysis itself. By permease structural modeling, mutagenesis, and kinetic parameter analysis, we showed that Gap1 and Can1 need to switch to an intermediary conformational state and persist a minimal time in this state after binding the substrate to trigger their endocytosis. This down-regulation depends on the Rsp5 ubiquitin ligase and involves the recruitment of arrestin-like adaptors, resulting in the ubiquitylation and endocytosis of the permease.<p><p>Our work shows the importance of the structural analysis of yAAPs to get further insight into the different aspects of their function and regulation. We validate the use of a bacterial APC transporter, AdiC, to construct three-dimensional models of yAAPs that can be used to guide experimental analyses and to provide a molecular framework for data interpretation. Our results contribute to a better understating of the recognition mode of amino acids by their permeases, and the regulation of this transport in response to substrate binding. / Doctorat en Sciences / info:eu-repo/semantics/nonPublished

O metabolismo da glutamina (Gln) é alvo de atenções recentes para a compreensão da reprogramação metabólica para o suprimento energético das células tumorais em proliferação e para o desenvolvimento de novas estratégias terapêuticas em câncer. Tanto a absorção de glutamina quanto a taxa de glutaminólise, o catabolismo da Gln para gerar adenosina trifosfato (ATP) e lactato na mitocôndria estão aumentados em diferentes tumores. A Gln e glicose participam do processo da proliferação de células tumorais tanto na produção de (ATP) como no fornecimento de produtos intermediários utilizados na síntese de macromoléculas e Gln é utilizado para anaplerose do ciclo do ácido tricarboxílico. Nesse estudo, nosso objetivo foi analisar a expressão dos genes envolvidos na glutaminólise: ASCT2, LAT1, GLS, GLSISO1, GLSISO2, GLS2, GOT1, GOT2, GLUD1 e GPT2 em astrocitomas de diferentes graus de malignidade (AGI-AGIV), classificados de acordo com a Organização Mundial de Saúde (OMS), em relação às expressões em tecidos cerebrais não neoplásicos e correlacionar os níveis de expressão destes genes aos dados clínicos. PCR quantitativo em tempo real (qRT-PCR) foi realizado em 175 amostras, sendo 22 dentre estes de tecidos não neoplásicos. Observou-se tempo de sobrevida menor entre os pacientes com hiperexpressão de LAT1, na presença de hipoexpressão de ASCT2. A expressão de GLS foi comparativamente maior que a expressão de GLS2 entre os astrocitomas de diferentes graus de malignidade, corroborando descrições prévias de que GLS relaciona-se à proliferação tumoral e GLS2 à supressão do crescimento tumoral. Observou-se, adicionalmente, o aumento da associação das expressões destes genes conforme o aumento do grau de malignidade, culminando em GBM, onde estas correlações foram estatisticamente significativas. Apesar da demonstração da ativação gradativa desta via da glutaminólise com o aumento da malignidade, a hiperexpressão dos genes relacionados a esta via mostrou-se hiperexpressa em apenas um subgrupo de pacientes com GBM. Esta observação ressalta a heterogeneidade observada em GBM e a elegibilidade restrita deste subgrupo a eventuais estratégias terapêuticas que forem desenvolvidas com alvos nesta via / The metabolism of glutamine (Gln) is the target of recent attentions to understand the metabolic reprogramming of cancer cell for the energetic needs for cell proliferation, and to develop new cancer therapeutic strategies. Glutamine absortion and glutamine conversion to ATP and lactate in the mitochondria through glutaminolysis are both increased in different cancer types. Gln and glucose participate in metabolic pathways which provide ATP and intermediate substrats for synthesis of macromolecules, and Gln is used for anaplesoris of tricyclic acid cycle. The aims of the present study were to analyze the differential mRNA expressions of genes involved in the glutaminolysis pathways: ASCT2, LAT1, GLS, GLSISO1, GLSISO2, GLS2, GOT1, GOT2, GLUD1 e GPT2 in astrocytomas of different grades of malignancy (WHO grades I to IV) compared to non-neoplastic brain tissues, and to correlate these expression data to clinical outcome. Shorter overall survival time was observed among a subset of GBM patients presenting hyperexpression of LAT1 while ASCT2 was hypoexpressed. GLS expression was comparatively higher than GLS2 expression among astrocytomas of different grades of malignancy, which corrobates previous reports relating GLS to tumor proliferation and GLS2 to suppression of tumor growth. Additionally, increased gene expression correlation was observed in parallel to the increase of malignancy, and these associated expressions were significant among GBM. Although a stepwise increase of the glutaminolysis pathway was demonstrated with the increase of malignancy in astrocytomas, the hyperexpression of genes involved in this pathway were detected only in a subset of GBM patients. This finding confirm the heterogeneity observed among GBM, and highlights the fact that any therapeutic strategy aiming this pathway will be restricted to a subset of GBM patients

O metabolismo da glutamina (Gln) é alvo de atenções recentes para a compreensão da reprogramação metabólica para o suprimento energético das células tumorais em proliferação e para o desenvolvimento de novas estratégias terapêuticas em câncer. Tanto a absorção de glutamina quanto a taxa de glutaminólise, o catabolismo da Gln para gerar adenosina trifosfato (ATP) e lactato na mitocôndria estão aumentados em diferentes tumores. A Gln e glicose participam do processo da proliferação de células tumorais tanto na produção de (ATP) como no fornecimento de produtos intermediários utilizados na síntese de macromoléculas e Gln é utilizado para anaplerose do ciclo do ácido tricarboxílico. Nesse estudo, nosso objetivo foi analisar a expressão dos genes envolvidos na glutaminólise: ASCT2, LAT1, GLS, GLSISO1, GLSISO2, GLS2, GOT1, GOT2, GLUD1 e GPT2 em astrocitomas de diferentes graus de malignidade (AGI-AGIV), classificados de acordo com a Organização Mundial de Saúde (OMS), em relação às expressões em tecidos cerebrais não neoplásicos e correlacionar os níveis de expressão destes genes aos dados clínicos. PCR quantitativo em tempo real (qRT-PCR) foi realizado em 175 amostras, sendo 22 dentre estes de tecidos não neoplásicos. Observou-se tempo de sobrevida menor entre os pacientes com hiperexpressão de LAT1, na presença de hipoexpressão de ASCT2. A expressão de GLS foi comparativamente maior que a expressão de GLS2 entre os astrocitomas de diferentes graus de malignidade, corroborando descrições prévias de que GLS relaciona-se à proliferação tumoral e GLS2 à supressão do crescimento tumoral. Observou-se, adicionalmente, o aumento da associação das expressões destes genes conforme o aumento do grau de malignidade, culminando em GBM, onde estas correlações foram estatisticamente significativas. Apesar da demonstração da ativação gradativa desta via da glutaminólise com o aumento da malignidade, a hiperexpressão dos genes relacionados a esta via mostrou-se hiperexpressa em apenas um subgrupo de pacientes com GBM. Esta observação ressalta a heterogeneidade observada em GBM e a elegibilidade restrita deste subgrupo a eventuais estratégias terapêuticas que forem desenvolvidas com alvos nesta via / The metabolism of glutamine (Gln) is the target of recent attentions to understand the metabolic reprogramming of cancer cell for the energetic needs for cell proliferation, and to develop new cancer therapeutic strategies. Glutamine absortion and glutamine conversion to ATP and lactate in the mitochondria through glutaminolysis are both increased in different cancer types. Gln and glucose participate in metabolic pathways which provide ATP and intermediate substrats for synthesis of macromolecules, and Gln is used for anaplesoris of tricyclic acid cycle. The aims of the present study were to analyze the differential mRNA expressions of genes involved in the glutaminolysis pathways: ASCT2, LAT1, GLS, GLSISO1, GLSISO2, GLS2, GOT1, GOT2, GLUD1 e GPT2 in astrocytomas of different grades of malignancy (WHO grades I to IV) compared to non-neoplastic brain tissues, and to correlate these expression data to clinical outcome. Shorter overall survival time was observed among a subset of GBM patients presenting hyperexpression of LAT1 while ASCT2 was hypoexpressed. GLS expression was comparatively higher than GLS2 expression among astrocytomas of different grades of malignancy, which corrobates previous reports relating GLS to tumor proliferation and GLS2 to suppression of tumor growth. Additionally, increased gene expression correlation was observed in parallel to the increase of malignancy, and these associated expressions were significant among GBM. Although a stepwise increase of the glutaminolysis pathway was demonstrated with the increase of malignancy in astrocytomas, the hyperexpression of genes involved in this pathway were detected only in a subset of GBM patients. This finding confirm the heterogeneity observed among GBM, and highlights the fact that any therapeutic strategy aiming this pathway will be restricted to a subset of GBM patients

Gliomas are the most common primary brain tumours and are associated with poor prognosis. Among them, diffuse gliomas – which include their most aggressive form glioblastoma (GBM) – are known to be highly infiltrative. The diagnosis and follow-up of gliomas rely on positron emission tomography (PET) and magnetic resonance imaging (MRI). However, these imaging techniques do not currently allow to assess the whole extent of such infiltrative tumours nor to anticipate their preferred invasion patterns, leading to sub-optimal treatment planning. Mathematical tumour growth modelling has been proposed to address this problem. Reaction-diffusion tumour growth models, which are probably the most commonly used for diffuse gliomas growth modelling, propose to capture the proliferation and migration of glioma cells by means of a partial differential equation. Although the potential of such models has been shown in many works for patient follow-up and therapy planning, only few limited clinical applications have seemed to emerge from these works. This thesis aims at revisiting reaction-diffusion tumour growth models using state-of-the-art medical imaging and data processing technologies, with the objective of integrating multi-parametric PET/MRI data to further personalise the model. Brain tissue segmentation on MR images is first addressed with the aim of defining a patient-specific domain to solve the model. A previously proposed method to derive a tumour cell diffusion tensor from the water diffusion tensor assessed by diffusion-tensor imaging (DTI) is then implemented to guide the anisotropic migration of tumour cells along white matter tracts. The use of dynamic [S-methyl-11C]methionine ([11C]MET) PET is also investigated to derive patient-specific proliferation potential maps for the model. These investigations lead to the development of a microscopic compartmental model for amino acid PET tracer transport in gliomas. Based on the compartmental model results, a novel methodology is proposed to extract parametric maps from dynamic [11C]MET PET data using principal component analysis (PCA). The problem of estimating the initial conditions of the model from MR images is then addressed by means of a translational MRI/histology study in a case of non-operated GBM. Numerical solving strategies based on the widely used finite difference and finite element methods are finally implemented and compared. All these developments are embedded within a common framework allowing to study glioma growth in silico and providing a solid basis for further research in this field. However, commonly accepted hypothesis relating the outlines of abnormalities visible on MRI to tumour cell density iso-contours have been invalidated by the translational study carried out, leaving opened the questions of the initialisation and the validation of the model. Furthermore, the analysis of the temporal evolution of real multi-treated glioma patients demonstrates the limitations of the formulated model. These latter statements highlight current obstacles to the clinical application of reaction-diffusion tumour growth models and pave the way to further improvements. / Les gliomes sont les tumeurs cérébrales primitives les plus communes et sont associés à un mauvais pronostic. Parmi ces derniers, les gliomes diffus – qui incluent la forme la plus agressive, le glioblastome (GBM) – sont connus pour être hautement infiltrants. Le diagnostic et le suivi des gliomes s'appuient sur la tomographie par émission de positons (TEP) ainsi que l'imagerie par résonance magnétique (IRM). Cependant, ces techniques d'imagerie ne permettent actuellement pas d'évaluer l'étendue totale de tumeurs aussi infiltrantes ni d'anticiper leurs schémas d'invasion préférentiels, conduisant à une planification sous-optimale du traitement. La modélisation mathématique de la croissance tumorale a été proposée pour répondre à ce problème. Les modèles de croissance tumorale de type réaction-diffusion, qui sont probablement les plus communément utilisés pour la modélisation de la croissance des gliomes diffus, proposent de capturer la prolifération et la migration des cellules tumorales au moyen d'une équation aux dérivées partielles. Bien que le potentiel de tels modèles ait été démontré dans de nombreux travaux pour le suivi des patients et la planification de thérapies, seules quelques applications cliniques restreintes semblent avoir émergé de ces derniers. Ce travail de thèse a pour but de revisiter les modèles de croissance tumorale de type réaction-diffusion en utilisant des technologies de pointe en imagerie médicale et traitement de données, avec pour objectif d'y intégrer des données TEP/IRM multi-paramétriques pour personnaliser davantage le modèle. Le problème de la segmentation des tissus cérébraux dans les images IRM est d'abord adressé, avec pour but de définir un domaine propre au patient pour la résolution du modèle. Une méthode proposée précédemment permettant de dériver un tenseur de diffusion tumoral à partir du tenseur de diffusion de l'eau évalué par imagerie DTI a ensuite été implémentée afin de guider la migration anisotrope des cellules tumorales le long des fibres de matière blanche. L'utilisation de l'imagerie TEP dynamique à la [S-méthyl-11C]méthionine ([11C]MET) est également investiguée pour la génération de cartes de potentiel prolifératif propre au patient afin de nourrir le modèle. Ces investigations ont mené au développement d'un modèle compartimental pour le transport des traceurs TEP dérivés des acides aminés dans les gliomes. Sur base des résultats du modèle compartimental, une nouvelle méthodologie est proposée utilisant l'analyse en composantes principales pour extraire des cartes paramétriques à partir de données TEP dynamiques à la [11C]MET. Le problème de l'estimation des conditions initiales du modèle à partir d'images IRM est ensuite adressé par le biais d'une étude translationelle combinant IRM et histologie menée sur un cas de GBM non-opéré. Différentes stratégies de résolution numérique basées sur les méthodes des différences et éléments finis sont finalement implémentées et comparées. Tous ces développements sont embarqués dans un framework commun permettant d'étudier in silico la croissance des gliomes et fournissant une base solide pour de futures recherches dans le domaine. Cependant, certaines hypothèses communément admises reliant les délimitations des anormalités visibles en IRM à des iso-contours de densité de cellules tumorales ont été invalidée par l'étude translationelle menée, laissant ouverte les questions de l'initialisation et de la validation du modèle. Par ailleurs, l'analyse de l'évolution temporelle de cas réels de gliomes multi-traités démontre les limitations du modèle. Ces dernières affirmations mettent en évidence les obstacles actuels à l'application clinique de tels modèles et ouvrent la voie à de nouvelles possibilités d'amélioration. / Doctorat en Sciences de l'ingénieur et technologie / info:eu-repo/semantics/nonPublished